A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

NCT05044988 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+/HER2- Advanced and/or Metastatic Breast Cancer

Interventions

DRUG: HS-10342

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.